Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.58 |
| ▸ | CA2 | P00918 | 3/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.51 |
| ▸ | PTGS1 | P23219 | 9/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 8/20 | 0.46 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.41 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.41 |
| ▸ | CA12 | O43570 | 1/20 | 0.40 |
| ▸ | CA1 | P00915 | 1/20 | 0.40 |
| ▸ | CA9 | Q16790 | 1/20 | 0.40 |
| ▸ | ACHE | P22303 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23674205 | 0.81 | L3MBTL1 (0.43) | L3MBTL1POLBCA2PTPN11 | |
| SCHEMBL19333353 | 0.80 | L3MBTL1 (0.60) | L3MBTL1POLBCA2NPC1CA12 | |
| SCHEMBL19333346 | 0.79 | CA2 (0.47) | L3MBTL1POLBCA2PTGS1PTGS2 | |
| SCHEMBL5607024 | 0.78 | L3MBTL1 (1.00) | L3MBTL1POLBCA2NPC1CA12 | |
| SCHEMBL21544195 | 0.77 | L3MBTL1 (0.70) | L3MBTL1POLBCA2NPC1CA12 | |
| SCHEMBL15614459 | 0.77 | L3MBTL1 (0.70) | L3MBTL1POLBCA2NPC1CA12 | |
| SCHEMBL19333319 | 0.75 | PTGS1 (0.48) | CA2PTGS1PTGS2SLC22A12CA1 | |
| SCHEMBL17914522 | 0.75 | L3MBTL1 (0.68) | L3MBTL1POLBCA2NPC1PTGS1 | |
| SCHEMBL2737222 | 0.75 | L3MBTL1 (0.73) | L3MBTL1POLBCA2NPC1CA12 | |
| SCHEMBL27183374 | 0.75 | L3MBTL1 (0.68) | L3MBTL1POLBCA2NPC1CA12 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100240630-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Myriad Pharmaceuticals, Inc.. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100240630-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | Myriad Pharmaceuticals, Inc.. (US) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240630-A1 | COMPOUNDS AND THERAPEUTIC USES THEREOF | HAVCR2, FURIN, SARS1 | L3MBTL1 2822/4885POLB 1667/4885CA2 1757/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.